Print Friendly, PDF & Email

October 15th: Pack Your Pink Bag and Join our Journey!

That’s

That’s the spirit! Kathy McEvoy shares the lessons she learned through her journey as a breast cancer survivor.

What common goal do an American bride, an Indian doctor and a French engineer share? A key global theme… they are all focused on the fight against breast cancer, a prevalent cancer in the world today.

GE Healthcare joins them to help amplify and extend the reach of their life saving message: early detection is key to increasing the chances of surviving this disease.

In 1999, GE Healthcare pioneered the world’s first digital mammography system. Last year, to commemorate this 10th anniversary as well as the Company’s long-standing commitment to fighting breast cancer and promoting awareness, GE Healthcare created a digital wall, Breast Cancer Emotion. This platform enables people around the globe to personally share their insights and experiences, as well as disease information and events.

An invitation to GE’s Journey
We’ve started our journey and continue to meet those who are involved in the global fight against breast cancer. And the journey continues…

The more we travel, be it via train, airplane and cyberspace, the more people we encounter whose insights and advice add meaning and value to our efforts.

Would you like to join our journey and paint the virtual world pink? Come follow @GEHealthcare on Twitter on October 15th (#GEJourney) – get in the zone of those who are sharing their story on Breast Cancer Emotion from every zone around the globe. Starting in Australia, you are invited to follow the sun with us on a trip that will take us all the way to the USA’s West Coast. All GE Healthcare sites will be painted pink to show our support for breast cancer survivors and their families.

Help spread the word on October 15th, Breast Cancer Awareness Day: Join the #GEJourney on Twitter; pass the message on!

****************

Fast Facts
· Around the world, more than 1 million people annually are diagnosed with breast cancer.
· 1 in 10 of all new cancers diagnosed worldwide each year is breast cancer
· Breast cancer is the most common cancer in women in both developing and developed areas. Unfortunately, it is also the principle cause of death from cancer among women globally.

Given these statistics, what is being done at GE Healthcare to address this health challenge?

Since the 1960s, GE Healthcare has been a global leader in the field of breast cancer detection through mammography devices. Today there are about 17,700 GE mammography systems in use worldwide.

In 1999, GE Healthcare was the first company to introduce full-field digital mammography (FFDM). GE estimates that since then, tens of millions of examinations have been performed with its diagnostic imaging technologies worldwide. As investment in innovation is key, GE has spent 13 years and more than $100 million developing the full-field digital mammography technology, GE Healthcare Senographe® systems, and continues to invest heavily in new cutting-edge technologies to detect the pathology before the onset. Approximately 3,700 GE Healthcare Senographe® digital systems are currently being used in the world — more than 90% of them still work with their original detector, proving our commitment and our reliability towards detecting breast cancer.

In 2009, healthcare technology research organization KLAS ranked GE Healthcare Senographe DS as the best digital mammography system on the market, based on a survey of healthcare providers.

Through its own research as well as partnerships with other industry innovators, GE Healthcare continues to research and develop advanced technologies with the goal of improving detection and reducing unnecessary biopsies in the future. Today, not all breast cancer is seen with mammography, and we are working on further research and new technologies to detect breast cancer at the earliest stage. Based on scientific studies, the use of supplemental screening with ultrasound or magnetic resonance imaging may be appropriate in addition to mammography for women at increased risk of breast cancer.